Definition of the Marfan Syndrome
Marfan syndrome (MFS) was first described in 1896 by Antoine Marfan, a pediatrician in Paris. Unlike many other diseases, there is equal distribution between the sexes and in all parts of the world. MFS is inherited in an autosomal dominant pattern, or caused by spontaneous mutation and is about as frequent as mucoviscidosis. The mutation is located on chromosome 15q21 (Marfan locus). This long arm of the chromosome 15 includes the gene encoding for fibrilline-1. This leads to a disturbed synthesis of microfibrils and thus elastic fibers.
Pathology of the Marfan Syndrome
Marfan syndrome is an autosomal dominant disorder of the connective tissue. It affects multiple systems, e.g. the cardiovascular and skeletal systems and the eyes. It occurs in 1/5000 live births.
Three body systems are mainly affected:
Ocular system (eyes): lens dislocation.
- Musculoskeletal system: dolichostenomelia (decreased upper: lower segment ratio), Arachnodactyly, thoracic cage deformities.
- Cardiovascular system (heart/aorta): aortic dissection, mitral valve insufficiency.
The degree of the manifestations varies to a high extent! The main cause of death, aortic dissection, is, however, often not detected. Typical manifestations of neonatal MFS are, in addition to those mentioned above, dolichocephaly, malar hypoplasia, enophthalmos, retrognathia and an impaired range of motion of peripheral joints.
Genetics of the Marfan syndrome
- Mutation in FBN 1 gene on chromosomes which encodes fibrillin-1
- 75% patients with MFS have affected parents
- 25% de novo mutation
- Tall stature
- Long headed
- Arachnodactyly (long thin digits)
- Hyperextensible joints
- High arched palate
- Scoliosis, kyphosis, slipping off vertebrae
- Pectus excavatum
- Ectopia lentis: Dislocation of the lenses
- Cardiovascular symptoms are main cause of morbidity and mortality
- Degeneration of the media of the vessel walls
- Dilated, incompetent aortic root with valvular incompetence
- Mitral valve prolapse and regurgitation
- Aneurysms in aorta may dissect or rupture
- Monitoring by echocardiography is required!
Diagnosis of the Marfan Syndrome and Ghent Nosology
Ghent nosology was introduced in 1996 and has made a diagnosis of MFS easier worldwide by resuming all diagnostic criteria. If the family history is negative, three major criteria in two different body systems must be present and a third system has to be involved. It was revised in 2010. There are seven new criteria that lead to a diagnosis.
In the absence of a family history of MFS:
- Aortic root Z-score ≥ 2 AND ectopia lentis
- Aortic root Z-score ≥ 2 AND an FBN1 mutation
- Aortic root Z-score ≥ 2 AND a systemic score > 7 points
- Ectopia lentis AND FBN1 mutation with known aortic pathology
In the presence of a family history of MFS:
- Ectopia lentis
- Systemic score ≥ 7
- Aortic root Z-score ≥ 2
Points for systemic score:
Wrist AND thumb sign = 3 (wrist OR thumb sign = 1)
- Pectus carinatum deformity = 2 (pectus excavatum or chest asymmetry = 1)
- Hindfoot deformity = 2 (plain pes planus = 1)
- Dural ectasia = 2
- Protrusio acetabuli = 2
- Pneumothorax = 2
- Reduced upper segment/lower segment ratio AND increased arm/height AND no severe scoliosis = 1
- Scoliosis or thoracolumbar kyphosis = 1
- Reduced elbow extension = 1
- Facial features (3/5) = 1 (dolichocephaly, enophthalmos, down-slanting palpebral fissures, malar hypoplasia, retrognathia)
- Skin striae (stretch marks) = 1
- Myopia > 3 diopters = 1
- Mitral valve prolapse ¼ 1
A systemic participation is available when 7 or more points are reached.
Treatment of Marfan Syndrome
Patients can only be treated individually to debilitate the symptoms. What is most important is to have regular appointments with ophthalmologists, cardiologists and orthopedic specialists, as they treat the systems that are mainly affected. It is crucial to monitor the aortic root diameter assessed echocardiographically. Prospective and retrospective trials have shown that propanol and atenolol can slow down aortic dilatation, resulting in an increased usage of beta blockers. This also helps prevent or forgo necessary cardiac surgery.
Life expectancy for patients with MFS has increased in the past few years. This is mainly due to cardiac surgery that patients undergo soon after the diagnosis. Thus, rupture and dissection of the aorta can be prevented.
- Cardiology, genetics, ophthalmology, orthopedics, cardiothoracic surgery
- Follow with echo
- Angiotensin II inhibitors/transforming growth factor-beta inhibitors
- Strict blood pressure control
- Aortic graft for aortic dilation > 5 cm
- Avoid caffeine, stimulants, heavy exercise
- Treat scoliosis